BioSpace News Archive

HUTCHMED Limited announces that the Center for Drug Evaluation of China’s National Medical Products Administration has granted Breakthrough Therapy Designation to savolitinib for the treatment of locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with mesenchymal epithelial transition factor amplification who have failed at least two lines of standard therapies.

Delve Bio, a pioneer in metagenomic next-generation sequencing for infectious diseases, announced the appointment of Jim Stuart as chief commercial officer and Jay Wohlgemuth, M.D., to the board of directors.

Edwards Lifesciences Corporation (NYSE: EW) today announced it is scheduled to present at the 2023 Wells Fargo Healthcare Conference on Thursday, September 7, 2023.

National Resilience, Inc. and Lifera have entered into a non-binding term sheet for the development of biopharma manufacturing capacity in Riyadh, Saudi Arabia.

Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announced that management will be presenting virtually at the H.C. Wainwright 25th Annual Global Investment Conference.

Adial Pharmaceuticals, Inc. announced that the Chief Medical Officer of Adial, Bankole Johnson, D.SC., M.D., and Key Opinion Leaders Jonathan Chick, M.D., Hannu Alho, M.D., Otto Lesch, M.D., and Giovanni Addolorato, M.D., will be presenting at the European Society for Biomedical Research on Alcoholism, taking place September 1-3, 2023, in Graz, Austria.

Nexus Pharmaceuticals LLC announced that the U.S. Food and Drug Administration (FDA) issued a notice in the Federal Register that ephedrine sulfate should not be bulked by compounding facilities.

Empyrean Medical Systems, Inc. (“Empyrean”), MagCorp Inc. (“MagCorp”), and MetOx Technologies, Inc. (“MetOx”) today announced a strategic collaboration agreement to accelerate the large-scale development of novel technology that will enable commercial production of next generation, state-of-the-art radiation therapy technology for cancer treatment.

Every successful medicine has its origin story. And research like this is the soil from which new drugs are born.

The GALACELA Phase 2 trial (NCT05856448) is a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of GLPG3667 in adults with active SLE.